Rotate the site of injection to avoid irritation or sterile abscess formation with repeat administration. Intramuscular Depot injection (fluphenazine decanoate or . PACKAGE LEAFLET: INFORMATION FOR THE USER. Modecate® 25mg/ml Injection fluphenazine decanoate. Is this leaflet hard to see or read? Phone . ADMINISTRATION). Fluphenazine decanoate is not indicated for the management of severely agitated psychotic patients or psychoneurotic.
|Published (Last):||18 August 2011|
|PDF File Size:||2.19 Mb|
|ePub File Size:||5.49 Mb|
|Price:||Free* [*Free Regsitration Required]|
Minor Due to the potential for QT prolongation and torsade de pointes TdPcaution is advised when administering bedaquiline with fluphenazine.
Modecate Injection 25mg/ml – Summary of Product Characteristics (SmPC) – (eMC)
Rate and extent of absorption vary with route of administration; oral tablet absorption is erratic and variable. However, melatonin co-administration resulted in increased feelings of cognitive impairment compared to thioridazine alone. Minor Injectable minocycline contains magnesium sulfate heptahydrate. Also, the anticholinergic decanpate of phenothiazines can be additive to those of amantadine, and may increase the risk of antimuscarinic-related side effects.
However, only the vasoconstrictors metaraminol or noradrenaline fluphenazone be used, as adrenaline may further lower the blood pressure through interaction with the phenothiazine.
Intramuscular IM injection fluphenazine hydrochloride only: Elevated concentrations of phenothiazines occurring through inhibition of CYP2D6 may increase the risk of adverse effects, including QT prolongation and torsade de pointes. Because no certain drug specificity was found for the observed outcomes, the authors concluded that underlying pathology or unidentified confounders could possibly explain the findings.
This blockade can cause an apparently paradoxical condition called ‘epinephrine reversal,’ which can lead to severe hypotension, tachycardia, and, potentially, myocardial infarction. Lower doses than usually prescribed for either the phenothiazine or the TCA may be required.
Additive drowsiness may also occur. Recurrence of psychotic symptoms may also occur, and the emergence of involuntary movement disorders such as akathisia, dystonia and dyskinesia has been reported. Theoretically, these phenothiazines may increase the risk of QT prolongation if ibsert with drugs with a risk of QT prolongation.
Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide: Fluphenazine is a primary substrate of CYP2D6 and it is not yet documented if pharmacokinetic interactions occur with kava kava. Oral medication should be discontinued after the first injection has been given.
Phenothiazines, including fluphenazine, should be used cautiously in those with hepatic disease. Overdosage should be treated symptomatically and supportively, extrapyramidal reactions will respond to oral or parenteral anti-parkinsonian drugs such as procyclidine or benzatropine.
It is not known if other hepatically-metabolized beta-blockers interact with the phenothiazines in this manner. Caution should be exercised during simultaneous use of these agents due to potential excessive CNS effects or additive hypotension. Fluphenazine and cobicistat are substrates and inhibitors of CYP2D6.
Fluphenazine is contraindicated for use in patients with known hypersensitivity to fluphenazine or other phenothiazine hypersensitivity.
Cases of QT prolongation and TdP have been reported during postmarketing use of fluvoxamine. Rotate the site of injection to avoid irritation or sterile abscess formation with repeat administration. Ethanol ingestion may further impair cognitive and motor skills and patients should be advised to avoid use of alcoholic beverages.
Moderate Asenapine has been associated with QT prolongation. Phenothiazines, like fluphenazine, may cause various forms of ocular disease.
Once dose-stabilized on depot formulation, this precaution may be modified for ambulatory patients as clinically appropriate for the individual. Additionally, sleep-related behaviors, such as sleep-driving, are more likely to occur during concurrent use of hypnotics and other CNS depressants than with use of a hypnotic alone. Agents that prolong decanoats QT interval could lead to torsade de pointes when combined with a phenothiazine, and therefore are generally not recommended for combined use; if they must be used, use with caution and with close monitoring.
A dose reduction of one or both drugs may be warranted. The likelihood of these pharmacodynamic interactions varies based upon the individual properties of the co-administered antipsychotic fluphenazjne. Torsade de pointes TdP and complete atrioventricular block have been reported.
While Modecate injection has been shown to be effective in acute states, it is particularly dwcanoate in the maintenance treatment of chronic patients who are unreliable at taking their oral medication, and also of those who do not absorb their oral phenothiazine adequately. Major Caution is advisable during concurrent use of brexpiprazole with other antipsychotics such as phenothiazines.
Moderate Additive effects may be seen when phenothiazines are used concomitantly with other drugs with antimuscarinic activity, such as diphenhydramine, a sedating H1-blocker. Moderate Monitor ECG for QT prolongation and monitor for additive sedation during concurrent use of lofexidine and fluphenazine. Mefloquine alone has not been reported to cause QT prolongation; however due to the lack of clinical data, mefloquine should be used with insett in patients receiving drugs that prolong the QT interval.
Use parenteral form cautiously in patients with asthma and those allergic to sulfites. Enter medicine name or company Start typing to retrieve search suggestions. Therefore, identify and address all possible causes of behavioral or psychological symptoms of dementia BPSD before considering an fluphenxzine. Sufficient washout time of drugs that are known to prolong the QT interval prior to administration of macimorelin iinsert recommended. Inssrt Patients receiving other drugs which have the potential for QT prolongation, such as phenothiazines, have an increased risk of developing proarrhythmias during bepridil therapy.
Moderate Dry mouth and drowsiness may occur in patients receiving cetirizine or levocetirizine; caution may be necessary during concomitant use of cetirizine or levocetirizine with phenothiazines. In general, the parenteral dose has been found to be approximately one-third to one-half the oral dose.
If eribulin and another drug that prolongs the Decanoqte interval, such as fluphenazine, must be coadministered, ECG monitoring is recommended; closely monitor the patient for QT interval prolongation. When administered as maintenance therapy, a single injection may be effective in controlling schizophrenic symptoms for up to four weeks or longer.